Dabbling in CD47, Pfizer infuses $25M into a biotech player touting positive monotherapy data
Pfizer is following Gilead, AbbVie, Boehringer and a string of biotech upstarts into the CD47 race, lining up its own shots at the “don’t eat me” signal that is shaping up to be the big cancer checkpoint target.
And it’s starting small.
With $25 million in initial investment, Pfizer is stacking up about 2.3 million shares in Trillium Therapeutics $TRIL for $10.88 per share — a 15% premium over its Friday close. Investors were quick to follow Pfizer’s lead, bidding up Trillium’s shares 40% Wednesday morning.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.